COVID-19 Vaccines

William O Hahn; Zanthia Wiley

doi:10.1016/j.idc.2022.01.008

COVID-19 Vaccines

Infect Dis Clin North Am. 2022 Jun;36(2):481-494. doi: 10.1016/j.idc.2022.01.008. Epub 2022 Jan 31.

Authors

William O Hahn¹, Zanthia Wiley²

Affiliations

¹ Division of Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA. Electronic address: willhahn@uw.edu.
² Division of Infectious Diseases, Department of Medicine, Emory University, Infectious Diseases Clinic, 550 Peachtree Street NE, 7th Floor - Medical Office Tower, Atlanta, GA 30308, USA.

Abstract

This article is a narrative review of the rapidly moving coronavirus disease 2019 vaccine field with an emphasis on clinical efficacy established in both randomized trials and postmarketing surveillance of clinically available vaccines. We review the major clinical trials that supported authorization for general use of the Janssen (Ad.26.CoV2), Pfizer-BioNTech (BNT162b2), and Moderna (mRNA-1273) vaccines and the publicly available postmarketing information with the goal of providing a broad, clinically relevant comparison of efficacy and safety. This review is primarily focused on the US market.

Keywords: COVID-19; Janssen (Ad.26.CoV2); SARS-CoV-2; Vaccine; mRNA vaccine; post-marketing vaccine surveillance; vaccine efficacy trials.

Publication types

Review

MeSH terms

BNT162 Vaccine
COVID-19 Vaccines / adverse effects
COVID-19* / prevention & control
Humans
Vaccines*

Substances

COVID-19 Vaccines
Vaccines
BNT162 Vaccine